Lionco(603669)2025-01-16 08:52Financial Performance Expectations - The company expects a net profit attributable to shareholders of approximately -120 million yuan for 2024, representing a reduction in losses of about 20.79% compared to the previous year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be around -165 million yuan, reflecting a reduction in losses of approximately 9.26% year-over-year[3]. - The projected operating revenue for 2024 is approximately 380 million yuan, indicating a year-over-year growth of about 93.06%[4]. - The operating revenue, excluding unrelated business income and income without commercial substance, is expected to be around 350 million yuan, showing a year-over-year increase of approximately 84.88%[4]. Sales and Marketing Strategies - The primary reason for the current period's losses is a decline in gross profit due to centralized procurement, which has led to sales gross profit not covering the period expenses[7]. - The company has increased its promotional efforts for centrally procured products, resulting in significant growth in sales revenue compared to the same period last year[7]. - The company is actively seeking CMO orders to maximize production capacity and leverage its production advantages[7]. - The company has adjusted its sales strategy to expand sales channels in private hospitals, contributing to substantial growth in sales revenue for cardiovascular products compared to the previous year[7]. Financial Reporting and Forecasting - The financial data provided is preliminary and has not been audited by registered accountants, with the final figures to be disclosed in the official annual report[9]. - The company does not foresee any significant uncertainties that could affect the accuracy of this earnings forecast[8].